Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidiol - GW Pharmaceuticals

Next Previous
Drug Profile

Cannabidiol - GW Pharmaceuticals

Alternative Names: CBD - GW Pharmaceuticals; CBD-OS - GW Pharmaceuticals; Epidiolex; Epidiolex/Epidyolex; EPIDIOLEXA; Epidyolex; GW-42003; GWP-42003; GWP-42003-P; JZP-926; JZP926-OS

Latest Information Update: 31 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GW Pharmaceuticals
  • Developer GW Pharmaceuticals; Jazz Pharmaceuticals Inc; University of Alabama at Birmingham; University of Utah
  • Class Alkenes; Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Cycloparaffins; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Phenols; Resorcinols; Skin disorder therapies; Small molecules
  • Mechanism of Action 5-HT1 serotonin receptor modulators; Antioxidants; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome; Cerebral ischaemia; Infantile spasms; Tuberous sclerosis; Myoclonic epilepsies
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dravet syndrome; Lennox-Gastaut syndrome; Tuberous sclerosis
  • Registered Seizures
  • Phase III Epilepsy; Infantile spasms; Rett syndrome
  • Phase II/III Blepharospasm
  • Phase II Autism spectrum disorder; Heroin-related disorders; Opioid-related disorders; Parkinson's disease; Sturge-Weber syndrome
  • Phase I Partial epilepsies
  • No development reported Cerebral ischaemia; Duchenne muscular dystrophy; Ovarian cancer
  • Discontinued Dyslipidaemias; Myoclonic epilepsies; Non-alcoholic fatty liver disease; Schizophrenia; Type 2 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 24 Jul 2026 Jazz Pharmaceuticals plans a phase II/III trial for Epilepsy (Adjunctive treatment, In children, In adolescent, In adults, In the elderly) in USA in September 2026 (PO) (NCT07723963)
  • 24 Jul 2026 Jazz Pharmaceuticals plans a phase III trial for Epileptic encephalopathy (Treatment experienced, In infants, In children, In adolescents, In adults, In the elderly) in October 2026 (PO) (NCT07723976)
  • 09 Apr 2026 Registered for Seizures in Taiwan (unspecified route) prior to April 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top